

The evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

SARS-CoV-2 infection in children, brain infection in COVID-19, virological characteristics of Omicron BA.2.75, COVID rebound

Peer reviewed journals featured:

- A systematic review on SARS-CoV-2 infection in children and implications for vaccination [here](#)
- Randomised clinical trial of metformin, ivermectin, and fluvoxamine for COVID-19 [here](#) and associated editorial [here](#)
- Narrative review on brain infection in COVID-19 patients [here](#)
- Observational studies on:
 - Comparison of severe maternal morbidities associated with specific SARS-CoV-2 variants [here](#) and associated commentary [here](#)
 - Healthcare utilisation in the 6 months following SARS-CoV-2 infection [here](#)
 - Durability of heterologous and homologous COVID-19 vaccine boosts [here](#)
 - Antibody response in immunocompromised patients with hematologic cancers [here](#)
 - Association of COVID-19 and influenza with risk of arterial and venous thrombosis among hospitalised patients [here](#)
 - Phenotypes of disease severity in hospitalised COVID-19 patients in the US [here](#)
 - Safety of COVID-19 vaccines in pregnancy [here](#) and associated commentary [here](#)
 - Long COVID and psychiatric disorders after COVID-19 hospitalisation [here](#)
 - Neurological and psychiatric risk trajectories after SARS-CoV-2 infection [here](#) and associated commentary [here](#)
 - Empirical evidence on the efficiency of backward contact tracing in COVID-19 [here](#)
 - A fourth COVID-19 vaccination in rituximab-treated patients [here](#)
 - Electronic nose (GeNose C19) for sniffing out COVID-19 [here](#)
- Commentary on health worker burnout and well-being in the US [here](#)

Letters and correspondence discussed:

- Challenges and opportunities for COVID-19 self-test data in the US [here](#)
- Risk of SARS-CoV-2 acquisition in health care workers according to cumulative patient exposure and preferred mask type [here](#)
- COVID-19 and microbiome diversity in sub-Saharan Africa [here](#) and author's reply [here](#)
- Comparative neutralisation profile of Omicron subvariants BA.2.75 and BA.5 [here](#)

Pre-peer review articles featured:

- Virological characteristics of the Omicron BA.2.75 variant [here](#)
- Risk factors associated with long COVID in the US [here](#)
- Waning of protection induced by prior BA.1/BA.2 infection against BA.5 infection [here](#)
- Risk factors for COVID-19 hospitalisation or death during the first Omicron surge in adults [here](#)
- Clinical effectiveness of COVID-19 booster against Omicron in long-term care facilities [here](#)
- The role of nightlife settings in sustained COVID-19 transmission [here](#)
- Further humoral immunity evasion of emerging Omicron BA.4 and BA.5 subvariants [here](#)
- Omicron BA.2, BA.4 & BA.5 serum neutralisation in patients receiving monoclonal antibodies [here](#)
- Recent prior SARS-CoV-2 infection and risk of Omicron infection and hospitalisation [here](#)

Guidance and reports

- The World Health Organization published its weekly COVID-19 epidemiological report [here](#)
- The National COVID-19 Clinical Evidence Taskforce released updated recommendations and clinical flowcharts [here](#)
- The US Association for the Advancement of Blood and Biotherapies (AABB) published guidelines on the use of COVID-19 convalescent plasma [here](#)
- US Centers for Disease Control published guidance on minimising the impact of COVID-19 on individuals, communities, and healthcare systems [here](#)

News and blogs

- A US research plan for long COVID [here](#)
- Moderna's Omicron BA.1 vaccine and the UK autumn booster program [here](#)
- The UK will not buy Evusheld owing to "insufficient data" on protection [here](#)
- How much virus does a person with COVID exhale? [here](#)
- Should parents delay kids' second COVID-19 vaccine? [here](#)
- COVID rebound is surprisingly common - even without Paxlovid [here](#)
- What have been the direct and indirect health impacts in England? [here](#)

[Click here](#) to subscribe to, and unsubscribe from, the evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on SARS-CoV-2 [vaccines](#), and [variants](#) of concern, and [post-acute sequelae of COVID-19 \(long COVID\)](#).